Neurocrine biosciences reports first quarter 2021 financial results

San diego, may 5, 2021 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the first quarter ended march 31, 2021 and provided revised full-year 2021 financial expense guidance. "our first quarter results reflect a lower than normal refill rate per patient due to the typical seasonal payor dynamics for ingrezza that were exacerbated by covid.
NBIX Ratings Summary
NBIX Quant Ranking